Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Takeda Pharmaceutical Co. (TAK) had Consolidated Net Income/Loss of $2.35B for the most recently reported fiscal year, ending 2023-03-31.
Income Statement Financials | |
$29.80B |
|
$2.35B |
|
$9.21B |
|
$20.60B |
|
$26.17B |
|
$3.63B |
|
$-854.07M |
|
$2.78B |
|
$2.78B |
|
$2.35B |
|
$2.35B |
|
Consolidated Net Income/Loss |
$2.35B |
$2.35B |
|
$3.63B |
|
$8.55B |
|
3.10B |
|
3.14B |
|
$0.76 |
|
$0.75 |
|
Balance Sheet Financials | |
$17.74B |
|
$12.52B |
|
$85.54B |
|
$103.29B |
|
$18.37B |
|
$29.92B |
|
$37.90B |
|
$56.26B |
|
$47.02B |
|
$-20.02B |
|
$47.02B |
|
3.11B |
|
Cash Flow Statement Financials | |
$7.23B |
|
$-4.49B |
|
$-5.25B |
|
$6.29B |
|
$3.95B |
|
$-2.34B |
|
$448.97M |
|
$-2.07B |
|
-- |
|
Fundamental Metrics & Ratios | |
0.97 |
|
-- |
|
-- |
|
0.39 |
|
0.69 |
|
69.11% |
|
12.18% |
|
12.18% |
|
28.68% |
|
9.31% |
|
7.87% |
|
$6.20B |
|
-- |
|
-- |
|
-- |
|
0.29 |
|
1.26 |
|
5.91 |
|
61.78 |
|
4.99% |
|
-11.72% |
|
2.27% |
|
3.05% |
|
$15.12 |
|
$1.97 |
|
$2.30 |